Systemic lupus erythematosus: The infl uence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques – A preliminary report. Benefi cial effect of immunosuppressive treatment on carotid intima media thickness

Acta Cardiologica

Volumn 70, Issue 2, 2015, Pages 169-175

  Kisiel, Bartłomiej ^a   Kruszewski, Robert ^a   Juszkiewicz, Aleksandra ^a   Raczkiewicz, Anna ^a   Bachta, Artur ^a   Kłos, Krzysztof ^a   Duda, Krzysztof ^a   Saracyn, Marek ^a   Szymański, Konrad ^b   Młoźniak Cieśla, Agnieszka ^c   Grabowska Jodkowska, Agnieszka ^c   Olesińskamd, Marzena ^c   Bogusławska Walecka, Romana ^a   Niemczyk, Stanisław ^a   Płoski, Rafał ^b   Tłustochowicz, Witold ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Immunosuppressive drugs; Intima media thickness; Systemic lupus erythematosus

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; AGE; COMMON CAROTID ARTERY; COMPLICATION; DISEASE COURSE; FOLLOW UP; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGE FACTORS; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84926473621     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.1080/ac.70.2.3073508     Document Type: Article

References (25)

1. Ward MM. Premature morbidity form cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-46.
2. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987; 14: 223-6.
3. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy R P, Kuller LH. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
4. Roman MJ, Shanker BA, Davis A, Lockshin LD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence of correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
5. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-9.
6. Esdaile JM, Abrahamowicz M, Grodzicky TY, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
7. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-67.
8. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010; 30: 1014-26.
9. Hassan AA, Habib HM, Eissa AA. Peripheral arterial disease in patients with systemic lupus erythematosus: a prospective controlled study. Int J Rheum Dis 2013; 16: 319-24.
10. Kiani AN, Post WS, Magder LS, Petri M. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) 2011; 50: 2071-9.
11. Sazliyana S, Mohd Shahrir MS, Norella Kong CT, Tan HJ, Hamidon BB, Azmi MT. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus 2011; 20: 1260-6.
12. Oryoji K, Kiyohara C, Horiuchi T, Tsukamoto H, Niiro H, Shimodo T, Akashi K, Yanase T. Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A. Mod Rheumatol 2014; 24: 86-92.
13. Liang HR, Socher SA, Larson MA, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18.
14. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez-Guerrero J, Snaith M, Sturfelt G. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-13.
15. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-53.
16. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, JaffM, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS, Zannad F, Zureik M. Mannheim carotid intima media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23: 75-80.
17. Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006; 33: 2458-63.
18. Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, Bernstein RM, Walker MG, Bruce IN. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007; 46: 983-8.
19. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-15.
20. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000; 9: 170-5.
21. Burgos PI, Vilá LM, Reveille JD, Alarcón GS. Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX). Lupus 2009; 18: 1303-8.
22. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumour necrosis factor α therapy and cardiovascular events in rheumatoid events. Arthritis Care Res 2011; 63: 522-9.
23. Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.
24. Greenberg JD, Kremer JM, Curtis JR Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH; CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576-82.
25. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49: 295-307.